Critical Outcome Technologies Inc. Announces the Issuance of Stock Options

LONDON, ONTARIO--(Marketwire - September 11, 2009) - Critical Outcome Technologies Inc. (COTI)(TSX VENTURE: COT) announced today that at its Board meeting of September 10, 2009 the Board of Directors approved the granting of 694,447 stock options to its nine Directors under the Company’s Stock Option Plan as a retainer for their service on the Board and its committees for the next year. The options vest immediately, have a life of five years and are exercisable at a price of $0.50 per share. The exercise price represents the closing price of the Company’s common shares on September 9, 2009, the last trade reported on the TSX Venture Exchange prior to the meeting date.

“The use of stock options to compensate the board members allows us to conserve our cash, as we move forward with our drug development plans and demonstrates the Directors’ belief and commitment to the Company’s future,” advised Company Chairman, Mr. John Drake.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. Currently, six targeted libraries of lead compounds are under active development; small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, adult acute leukemia, colorectal cancer and Alzheimer’s disease.

For more information, please visit our website www.criticaloutcome.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.